Tenecteplase
- Generic Name
- Tenecteplase
- Brand Names
- Metalyse, Tnkase
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 191588-94-0
- Unique Ingredient Identifier
- WGD229O42W
- Background
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease doma...
- Indication
用于溶栓治疗。
- Associated Conditions
- Cardiovascular Mortality
- Associated Therapies
- -
DiaMedica Updates ReMEDy2 Trial Timeline, Reports $50.2M Cash Position for Q3 2024
DiaMedica Therapeutics (DMAC) updated its ReMEDy2 trial protocol, including expanding the population to thrombolytic non-responders and increasing the interim analysis sample size to 200, expecting top-line results in Q4 2025. The Preeclampsia Phase 2 trial received regulatory approval and dosed its first patient. Financial highlights show a cash position of $50.2M as of September 30, 2024, with R&D expenses at $5.0M and G&A expenses at $1.9M. Cash runway extends into Q3 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath